Jacqueline C. Barrientos

Also affiliated with Mount Sinai Medical Center, Sylvester Comprehensive Cancer Center

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 16 papers. Top paper: “Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial”.

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Blood(2022)10.1182/blood.2021014960

N/A

5.5DataRank · unranked

240 citations

Victoria Wang, Curtis A. Hanson, Elisabeth Paietta, Susan O’Brien, Jacqueline C. Barrientos +17 more

Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes

Clinical Lymphoma Myeloma & Leukemia(2020)10.1016/j.clml.2020.02.001

N/A

1.3DataRank · unranked

27 citations

Vincent A. LoRe, Anthony R. Mato, Elise A. Chong, Jacqueline C. Barrientos, James N. Gerson +7 more

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

Leukemia(2021)10.1038/s41375-021-01257-7

N/A

0.578DataRank · unranked

46 citations

Leslie A. Andritsos, Versha Banerji, Jacqueline C. Barrientos, Seema A. Bhat, James S. Blachly +34 more

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

Blood Advances(2025)10.1182/bloodadvances.2024013474

N/A

0.292DataRank · unranked

6 citations

Victoria Wang, Curtis A. Hanson, Elisabeth Paietta, Susan O’Brien, Jacqueline C. Barrientos +16 more

No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib

Leukemia & lymphoma/Leukemia and lymphoma(2020)10.1080/10428194.2020.1845339

N/A

0.200DataRank · unranked

2 citations

Peter Hillmen, Gilles Salles, Jeff P. Sharman, Stephan Stilgenbauer, Oksana Gurtovaya +6 more

Activated CLL cells regulate IL-17F–producing Th17 cells in miR155-dependent and outcome-specific manners

JCI Insight(2022)10.1172/jci.insight.158243

N/A

0DataRank · unranked

4 citations

Gerardo Ferrer, Pui Yan Chiu, Rukhsana Aslam, Anita Ng, Florencia Palacios +9 more

Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia

Frontiers in Oncology(2022)10.3389/fonc.2022.897280

N/A

0DataRank · unranked

3 citations

Xiao‐Jie Yan, Wentian Li, Emanuela M. Ghia, Anton W. Langerak, Laura Z. Rassenti +22 more

Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2386

N/A

0DataRank · unranked

7 citations

Jacqueline C. Barrientos, Gerardo Ferrer, Morgan King-Richards, Yu-Ju Chen, Priyadarshini Ravichandran +11 more

Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Blood(2023)10.1182/blood-2023-182568

N/A

0DataRank · unranked

1 citations

James D’Olimpio, Andew gillis-Smith, Seung‐Tae Lee, Nirav N. Shah, Javier Pinilla‐Ibarz +9 more

Data from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model

(2023)10.1158/1078-0432.c.6605170.v2

N/A

0DataRank · unranked

0 citations

Jacqueline C. Barrientos, Gerardo Ferrer, Morgan King-Richards, Yu-Ju Chen, Priyadarshini Ravichandran +11 more

CLL crosstalk with naïve T cells enhances the differentiation of IL-22-producing T cells and CLL -cell survival

Leukemia(2024)10.1038/s41375-024-02463-9

N/A

0DataRank · unranked

0 citations

Florencia Palacios, Pui Yan Chiu, Kelly Wong, Alberto Bueno-Costa, Jacqueline C. Barrientos +7 more

Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

Blood Cancer Journal(2022)10.1038/s41408-022-00760-z

N/A

0DataRank · unranked

23 citations

Robert J. Kreitman, Enrico Tiacci, Leslie A. Andritsos, Versha Banerji, Jacqueline C. Barrientos +40 more

CLL intraclonal fractions exhibit established and recently acquired patterns of DNA methylation

Blood Advances(2020)10.1182/bloodadvances.2019000817

N/A

0DataRank · unranked

14 citations

Xiahoua Wang, Xiao‐Jie Yan, Marién Pascual, Manxia Fan, Jacqueline C. Barrientos +7 more

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Blood(2021)10.1182/blood.2020010146

N/A

0DataRank · unranked

35 citations

Curtis A. Hanson, Renee C. Tschumper, Connie Lesnick, Esteban Braggio, Elisabeth Paietta +17 more

Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course

Frontiers in Oncology(2021)10.3389/fonc.2021.640731

N/A

0DataRank · unranked

16 citations

Catherine Tang, Jennifer R. Brown, Siddha Kasar, Stacey M. Fernandes, Monica Colombo +14 more

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3815

N/A

0DataRank · unranked

116 citations

Lindsey E. Roeker, Ryan Jacobs, Brian T. Hill, Nicole Lamanna, Danielle M. Brander +49 more